[ADXS] Advaxis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 7.62 Change: 0.41 (5.69%)
Ext. hours: Change: 0 (0%)

chart ADXS

Refresh chart

Strongest Trends Summary For ADXS

ADXS is in the medium-term down -74% in 5 months. In the long-term down -96% below S&P in 2 years and up 198% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. The company?s Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. The company has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. Its products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA

Fundamental Ratios
Shares Outstanding EPS-1.97 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.44
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-57.87% ROE-63.14% ROI
Current Ratio12.18 Quick Ratio Long Term Debt/Equity Debt Ratio0.08
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities38.41 M Cash From Investing Activities-340 K Cash From Operating Activities-9.73 M Gross Profit
Net Profit-13.86 M Operating Profit-13.84 M Total Assets51.69 M Total Current Assets48.57 M
Total Current Liabilities3.99 M Total Debt30 K Total Liabilities4.32 M Total Revenue
Technical Data
High 52 week3.24 Low 52 week0.19 Last close0.36 Last change2%
RSI68.9 Average true range0.05 Beta0.47 Volume687.29 K
Simple moving average 20 days34.57% Simple moving average 50 days-10.89% Simple moving average 200 days-69.43%
Performance Data
Performance Week21.05% Performance Month-6% Performance Quart-55.31% Performance Half-75.2%
Performance Year-88.02% Performance Year-to-date87.95% Volatility daily17.12% Volatility weekly38.28%
Volatility monthly78.44% Volatility yearly271.73% Relative Volume327.71% Average Volume814.46 K
New High New Low

News

2019-01-15 20:10:30 | Edited Transcript of ADXS earnings conference call or presentation 15-Jan-19 4:00pm GMT

2019-01-11 08:38:43 | The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

2019-01-10 17:25:10 | Advaxis ADXS Reports Q4 Loss, Tops Revenue Estimates

2019-01-10 16:05:00 | Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update

2019-01-08 08:00:00 | Advaxis to Host Business Update Conference Call on January 15, 2019

2018-12-12 10:30:03 | Will Advaxis ADXS Report Negative Earnings Next Week? What You Should Know

2018-12-12 08:59:04 | Could Advaxis, Inc.’s NASDAQ:ADXS Investor Composition Influence The Stock Price?

2018-11-28 08:00:00 | Advaxis to Present at LD Micro Main Event

2018-11-06 08:00:00 | Advaxis to Present Poster Entitled “Natural Killer NK Cells Orchestrate the Antitumor Activities of Listeria monocytogenes Lm-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting

2018-11-02 08:00:00 | Advaxis Provides Update on Clinical Pipeline

2018-10-26 08:00:00 | Advaxis to Host Business Update Conference Call on November 2, 2018

2018-10-18 09:25:00 | Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence

2018-09-25 08:00:00 | Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-12 08:26:51 | The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

2018-09-11 12:00:16 | Advaxis Inc NASDAQ:ADXS: How Much Growth Is Left In Healthcare?

2018-09-11 09:20:00 | Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants

2018-09-11 08:25:17 | The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

2018-09-10 16:35:24 | Advaxis: Fiscal 3Q Earnings Snapshot

2018-09-10 16:30:00 | Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results

2018-09-07 09:25:00 | Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants

2018-09-07 07:55:48 | The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

2018-09-06 17:08:00 | Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

2018-09-04 08:00:00 | Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma

2018-08-28 07:45:00 | Recent Analysis Shows Liberty TripAdvisor, Control4, Ferro, Advaxis, Frontier Communications, and Newpark Resources Market Influences — Renewed Outlook, Key Drivers of Growth

2018-07-30 08:00:00 | Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer

2018-07-26 07:20:00 | Free Technical Research on Advaxis and Three More Biotech Equities

2018-07-19 09:00:45 | Why Investors Are Excited about Advaxis

2018-07-19 07:31:22 | FDA Lifts Hold on Clinical Trial: Major Boost for Advaxis

2018-07-18 11:09:03 | Analyzing Advaxis’s Financial Performance

2018-07-18 11:09:03 | Advaxis’s Research and Development Strategy

2018-07-18 08:08:12 | Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates

2018-07-17 07:10:00 | Blog Exposure - FDA Lifts Clinical Hold on Advaxis' Cancer Drug

2018-07-16 10:45:00 | Biotech Companies with Great Futures

2018-07-13 14:53:25 | Why Advaxis Stock Is Soaring Today

2018-07-13 11:37:42 | Advaxis Shares Soar After FDA Lifts Clinical Hold On Cancer Drug

2018-07-13 08:18:00 | Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

2018-07-13 08:00:00 | Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab

2018-07-10 08:00:00 | Advaxis Provides Update on MAA Filing and ADXS-HOT Program

2018-06-28 08:15:00 | New Research Coverage Highlights Knowles, Advaxis, G-III Apparel Group, LTD, National CineMedia, Haemonetics, and MACOM Technology Solutions — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-06-11 08:00:00 | Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

2018-06-07 22:50:01 | Edited Transcript of ADXS earnings conference call or presentation 7-Jun-18 3:00pm GMT

2018-06-07 09:25:24 | Advaxis: Fiscal 2Q Earnings Snapshot

2018-06-07 09:05:00 | Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

2018-06-07 07:45:00 | Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks

2018-06-06 08:00:00 | Advaxis Appoints Molly Henderson as Chief Financial Officer

2018-06-01 08:00:00 | Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting

2018-05-31 08:00:00 | Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018

2018-05-14 08:10:00 | Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results

2018-05-11 08:00:00 | Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

2018-04-23 08:00:00 | Advaxis Announces Executive Leadership Changes